Gene drug developer GenEdit has entered a multi-year partnership with Genentech, a Roche Group member, to develop therapies for autoimmune diseases.
The partnership will leverage GenEdit's NanoGalaxy platform to develop hydrophilic nanoparticle (HNP) medications for autoimmune diseases. Genentech will take charge of preclinical, clinical, regulatory development, and product commercialization. GenEdit will receive an upfront payment of USD 15 million in advancements and milestone payments, along with royalties from global net sales. The potential financial payout for GenEdit could reach up to USD 629 million.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.